SCHEMBL722458

SCHEMBL722458

COC(=O)c1ccc(NC(c2nc3ccc(OC)cc3n2C)C2CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.45
TP53 P04637 1/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
EPHX2 P34913 1/20 0.40
FPR1 P21462 1/20 0.39
THRB P10828 1/20 0.39
HPGDS O60760 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718794 0.93 NR1H4 (0.45) NR1H4TP53ALDH1A1MAPTTHRB
SCHEMBL3403102 0.86 GCG (0.45) NR1H4TP53ALDH1A1SMN1; SMN2NPC1
SCHEMBL3402066 0.85 NR1H4 (0.40) NR1H4TP53ALDH1A1MAPTMEN1
SCHEMBL717701 0.83 MEN1 (0.47) NR1H4TP53ALDH1A1MAPTSMN1; SMN2
SCHEMBL721554 0.82 IDH1 (0.42) NR1H4TP53MAPTTHRBMEN1
SCHEMBL718402 0.77 RCE1 (0.49) NR1H4TP53MAPTSMN1; SMN2NPC1
SCHEMBL718231 0.75 ALDH1A1 (0.50) TP53ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL719390 0.70 NPC1 (0.45) TP53ALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL718932 0.70 GCGR (0.49)
SCHEMBL28290816 0.70 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2NPC1EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NR1H4 811/4885TP53 293/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NR1H4 811/4885TP53 293/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.